These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 20862910

  • 21. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda).
    Jang DH, Rohe JC, Hoffman RS, Nelson LS.
    Ann Emerg Med; 2010 Mar; 55(3):303-4. PubMed ID: 20171465
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK, Ciric S, Boudriau S, Kisicki JC, Stauffer J.
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
    Davis MP.
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):823-31. PubMed ID: 27253690
    [Abstract] [Full Text] [Related]

  • 28. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM, Calleo VJ, Sullivan RW.
    Harm Reduct J; 2020 Oct 07; 17(1):71. PubMed ID: 33028340
    [Abstract] [Full Text] [Related]

  • 29. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
    Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, de Jong E, Gershon S.
    J Opioid Manag; 2006 Oct 07; 2(3):155-66. PubMed ID: 17319449
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
    Franchitto N, Jullian B, Salles J, Pelissier F, Rolland B.
    Expert Opin Drug Metab Toxicol; 2017 Jun 07; 13(6):669-677. PubMed ID: 28343423
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH, Xiang Q, Gould EM.
    Curr Med Res Opin; 2010 Aug 07; 26(8):1861-71. PubMed ID: 20521870
    [Abstract] [Full Text] [Related]

  • 39. Morphine/naltrexone.
    Duggan ST, Scott LJ.
    CNS Drugs; 2010 Jun 07; 24(6):527-38. PubMed ID: 20443648
    [Abstract] [Full Text] [Related]

  • 40. Unintentional rapid opioid detoxification: case report.
    Singh SM, Sharma B.
    Psychiatr Danub; 2009 Mar 07; 21(1):65-7. PubMed ID: 19270623
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.